Menu
Fechar
hrs4r
 I want to donate

The Metabolism and Cancer group adopts the view that cancer diseases are governed by metabolic reprogramming. Our laboratory pursues to understand the contribution of dysregulated metabolism in cancer initiation, drug resistance, and metastatic progression using laboratory-based experimental and computational tools through completion of clinical proof-of-efficacy in cancer patients.

Main lines of research
  1. Metabolism and cancer
  • Mechanistic understanding of metabolism-driven tumorigenesis
  • Metabolic mechanisms of cancer drug resistance
  • Identification of metabolic vulnerabilities as pharmacological targets for cancer therapy
  • Metabolomics and metabolic markers for early detection and clinical monitoring of cancer initiation, progression, and therapeutic resistance
  • Metabolo-epigenetics: Molecular aspects, computational modeling, and therapeutic development of precision medicine approaches

 

  1. Mitochondrial dynamics and cancer
  • Role of autophagy and mitochondria fussion/fission in the generation of cancer stem cells
  • Mitochondrial dynamics-targeted therapeutics for cancer therapy

 

  1. Natural biocompounds and cancer
  • Discovery and molecular characterization of natural biocompounds with anti-cancer properties
  • Pre-clinical development and clinical evaluation of natural biocompounds-based anti-cancer drugs

 

  1. Metabolo-immunotherapy
  • Identification of metabolic nodes and small-molecule metabolites essential for the regulation of immune checkpoints in cancer cells
  • Metabolic and dietary interventions to boost the efficacy of immune checkpoint inhibitors (ICIs).
  • Computational development and pre-clinical validation of in silico clinical trials platforms for testing new metabolo-immunotherapy approaches

 

  1. Computational systems biology in aging-driven cancer
  • Conceptual frameworks, stochastic tools, and wet-lab validation of metabolic and metabolo-epigenetic models of aging-driven cancer
Strategic objectives

To advance new metabolism-based anti-cancer therapeutics.

Publications

Espinoza I, Yang L, Steen TV, Vellon L, Cuyàs E, Verdura S, Lau L, Menendez JA, Lupu R

Binding of the angiogenic/senescence inducer CCN1/CYR61 to integrin a 6 ß 1 drives endocrine resistance in breast cancer cells.

Aging-Us, 2022, 14, 1200-1213 dx.doi.org/10.18632/aging.203882
0

Prognostic significance of the microbiome-adipose tissue axis in rectal cancer: protocol of a prospective observational study.

BJS Open, 2022, 6 dx.doi.org/10.1093/bjsopen/zrac009
0

Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism.

NATURE MEDICINE, 2022, 28, 752-765 dx.doi.org/10.1038/s41591-022-01749-8
0

Fatty acid synthase: a druggable driver of breast cancer brain metastasis.

EXPERT OPINION ON THERAPEUTIC TARGETS, 2022, 26, 1-18 dx.doi.org/10.1080/14728222.2022.2077189
0

Nuclear moonlighting of the secreted growth factor heregulin drives endocrine-resistant breast cancer independently of HER2/HER3 signaling.

AM J CANCER RES, 2022, 12, 2173-2188
0

Nuclear moonlighting of the secreted growth factor heregulin drives endocrine-resistant breast cancer independently of HER2/HER3 signaling

AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12, 2173-2188
0

Metformin and breast cancer: an opportunity for pharmacogenetics.

Aging-Us, 2022, 14, 5612-5613 dx.doi.org/10.18632/aging.204180
0

Laparoscopic Sleeve Gastrectomy in Patients with Severe Obesity Restores Adaptive Responses Leading to Nonalcoholic Steatohepatitis.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 dx.doi.org/10.3390/ijms23147830
0

Nutritional Niches of Cancer Therapy-Induced Senescent Cells.

Nutrients, 2022, 14 dx.doi.org/10.3390/nu14173636
0

Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 dx.doi.org/10.3390/ijms23179986
Competitive projects
Metabolism and Cancer

Dependencias metabólicas y regulación dietética de los puntos de control inmunitario: Nuevas dianas contra la resistencia a la inmunoterapia del cáncer

Codi oficial: PID2019-104055GB-I00 Start date:01/06/2020 Data fi: 31/05/2023 Investigador/a principal: JAVIER ABEL MENÉNDEZ MENÉNDEZ Organisme finançador: MINISTERIO DE ECONOMIA Y COMPETITIVIDAD MINECO / Ajuda: 242,000 €
Metabolism and Cancer

Ayuda de personal Miquel Servet

Codi oficial: CP20/00003 Start date:01/01/2021 Data fi: 31/12/2025 Investigador/a principal: ELISABET CUYÀS NAVARRO Organisme finançador: INSTITUTO DE SALUD CARLOS III Ajuda: 202,500 €
Transfer
Patents

Valiente Cortés Manuel, Priego Bendeck Neibla, Bosch Barrera Joaquim
MEANS FOR PREVENTING AND TREATING BRAIN METASTASIS
Número de publicació: EP20170382891
Data de publicació: 2019-06-26

Clinical Guidelines

- Nadal E,Bosch Barrera J,Cedrés S,Coves J,García Campelo R,Guirado M,López Castro R,Ortega AL,Vicente D,de Castro Carpeño J. SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020).Clin Transl Oncol. 2021. 23. (5):p. 980-987. IF:3,405. (Q3).

Job offers

Team

If you are a researcher and you are interested in collaborating with any of our research groups, please fill in this form.
I am interested in
If you are a student or you want to do an internship with any of our research groups, please fill in this form.
I am interested in

About IDIBGI!

 menu